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Background: Ten years have passed since Latvia became a Member State of the EU in 2004. As a result European
regulations, including those related to rare diseases and orphan drugs, have been applied to Latvian legislative
system. Orphan diseases have been recognized as a priority area for action in the public health system, though
there are significant differences in the national healthcare services for rare diseases among the EU States. This study
aims to determine situation in the field of rare diseases in Latvia and compare it with other European countries.
Methods: We used the national plan for rare diseases, EUCERD reports, Orphanet data, Latvian and European regulations,
publicly available data from the state agencies, and directly contacted drug manufacturers and wholesalers.
Results: National plan for rare diseases was developed and approved in 2013. Although there are no official designated
centers of expertise as well as no specific register for rare diseases. Newborns are screened for only two disorders:
phenylketonuria and congenital hypothyroidism. Currently 34 orphan drugs are available on Latvian market. Three
medicines (8.8%) are included in the reimbursement drug list, all indicated for Ph + CML. 15 drugs (44.1%) were
reimbursed within the framework of individual reimbursement system, and five drugs (14.7%) were provided within the
program of medicinal treatment of rare diseases in children.
Conclusions: Majority of orphan drugs authorized in the EU are not available in Latvia, moreover those drugs that are
available are often not accessible because they are insufficiently reimbursed. Besides, approval of the national plan might
be an important step towards improving situation in the field of rare diseases.
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Ten years have passed since Latvia became a member of
the European Union (EU) in 2004. Since then the EU
laws and regulations, including those related to rare
diseases, have been applied to Latvian legislative system.
According to the EU regulations disease is considered as
rare if it affects not more than five in ten thousand
people [1]. Most patients suffer from even rarer disor-
ders affecting one person in 100 000 or more [2], and it
could be very difficult to diagnose and manage these
conditions in relatively small populations. It is estimated
that between five and eight thousand different rare con-
ditions exist, affecting 6-8% of the population, conclud-
ing that about 30 million people are suffering from rare
disorders in the EU. Rare diseases are life-threatening or
chronically debilitating conditions of different origin. The* Correspondence: konstantins.logviss@gmail.com
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cancers, autoimmune, toxic and infectious diseases [3].
The EU offers a number of incentives to promote the
development of orphan medicines since, under normal
market conditions, pharmaceutical companies have little
interest in developing products intended for small num-
bers of patients. The incentives include assistance in drug
development, reduced fees for marketing authorization,
and protection from market competition once the drug is
authorized (10 years of marketing exclusivity) [1]. Orphan
designation refers to awarding of orphan status to a drug,
but marketing authorization refers to the approval to
market the product. Applications for orphan designa-
tion are examined by the European Medicines Agency’s
(EMA) Committee for Orphan Medicinal Products
(COMP), which adopts an opinion that is forwarded to
the European Commission, which afterwards decides
whether to grant an orphan designation for the drug in
question. Then pharmaceutical company submits a sin-
gle marketing authorization application to the EMA
under the centralized procedure. Once granted by theLtd. This is an Open Access article distributed under the terms of the Creative
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rization for orphan medicinal product is valid in all the
EU states. While many medicines may have received
an orphan designation, few have received a marketing
authorization. As of April 2014 there were more than a
thousand positive opinions on orphan designation and
only 72 orphan drugs authorized in the EU [4,5].
Generally there is a limited public awareness of the
rare diseases. The national healthcare services for these
disorders differ significantly among the EU countries,
resulting in unequal access to diagnostics and treatment
(including orphan medicines). An orphan drug is gener-
ally considered to be available when it is market autho-
rized and priced. To be accessible, however, it needs to
be reimbursed by public fund. Considering all the above
mentioned European Council recommended Member
States to establish and implement national plans for rare
diseases by the end of 2013 [2].
Aim of the study
This study aims to determine situation in the field of rare
diseases in Latvia and compare it with other European
countries. It includes visibility of these diseases, public
awareness, national strategy, research, diagnostics and
treatment, including availability and accessibility of or-
phan drugs.
Methods
The following sources of information were used to evalu-
ate situation in the field of rare diseases in Latvia: National
Plan for Rare Diseases (http://www.vm.gov.lv), EUCERD
2012, 2013 and 2014 Reports on the State of the Art of
Rare Disease Activities in Europe (http://www.eucerd.eu),
Statistics of the Center for Disease Prevention and Control
(http://www.spkc.gov.lv), Orphanet Latvia (http://www.
orpha.net/national/LV-LV) and laws and regulations of the
Cabinet of Ministers (http://likumi.lv). A literature review
was performed to compare Latvian situation in the field of
orphan medicines with other European countries.
Orphan drugs authorized in the EU were identified by
using EMA’s list of rare disease designations (http://www.
ema.europa.eu) and European Community Register of des-
ignated orphan medicinal products (http://ec.europa.eu/
health). Availability of orphan drugs on Latvian market
was determined by using the National Register of Human
Medicines maintained by the State Agency of Medicines
of Latvia (http://www.zva.gov.lv), as well as EUCERD
2012, 2013 and 2014 Reports (http://www.eucerd.eu), and
directly contacting drug manufacturers and wholesalers.
Drugs were considered to be available if they were
marketed/launched in Latvia according to data in at
least two of the above mentioned sources. The National
Health Service (http://www.vmnvd.gov.lv) data were used
to assess drug reimbursement including the nationalreimbursement list (as of January 2014) and individual
reimbursement data in 2008-2012. Children’s Clinical
University Hospital purchase procedure reports on
“Medicinal treatment for children with rare diseases”
program in 2010-2014 (http://www.bkus.lv) were analyzed
to identify orphan drugs provided within this program.
Drugs were considered to be accessible if they were
provided within some of the reimbursement mechanisms
mentioned above.
Results
National plan for rare diseases
Latvian national plan for rare diseases was written by the
working group, which included health care professionals,
representatives from the Ministry of Health (MoH) and
patient organizations. The plan was submitted to the
MoH for evaluation in December 2011 [6], and a public
consultation of the plan was launched in 2012 and the re-
sults were subsequently analyzed by the MoH. A number
of meetings with different stakeholders were held, and as a
result, the MoH developed and on 20 June 2013 approved
the National Plan for Rare Diseases for the period from
2013 to 2015 [7] in accordance with the European Council
recommendations of 8 June 2009 on an action in the field
of rare diseases [2].
There is no official definition for rare diseases in Latvia,
as stakeholders accept definition of the European Regula-
tion on Orphan Medicinal Products of a prevalence of no
more than 5 in 10 000 individuals, and that rare diseases
are life-threatening or chronically debilitating [6,7]. Main
strategic objectives of the plan are related to improving ac-
cess to information on rare diseases for health care profes-
sionals and patients with their families, as well as creation
of rare disease patient register. An important role of the
plan is dedicated to the prevention and early detection of
rare diseases, integrated medical and social care for patients,
and continuing education of health care professionals in the
field of rare diseases.
Centers of expertise
There are currently no official designated centers of
expertise for rare diseases in Latvia, but a meeting was
held in 2013 to discuss possible criteria for national cen-
ters of expertise [8]. A legal framework for centers of
expertise, including those for rare diseases, is expected
in the future. Several medical centers, that fulfill this role,
are currently recognized by reputation only [6]. For ex-
ample, the Children’s Clinical University Hospital (CCUH)
provides genetic services, as well as services for children
with haematological, oncological and endocrinological dis-
eases. Riga East Clinical University Hospital (RECUH) has
a specialized clinic of chemotherapy and haematology, in
which patients with haemophilia A and B, factor XII defi-
ciency and von Willebrand disease receive diagnostics and
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ma, Langerhans cell histiocytosis, Mantle-cell non-Hodgkin’s
lymphoma, multiple endocrine neoplasia, Ewing’s sarcoma,
Wilms’ tumour, Waldenstrom’s macroglobulinaemia and
others can be treated in this hospital as well. Pauls Stradins
Clinical University Hospital (PSCUH) provides services in
different rare disease areas, such as cardiology, angiology,
pulmonology, nephrology, endocrinology, gastroenterology,
oncology and ophthalmology. Latvian Pulmonary Hyper-
tension Center is a part of Center of Cardiology of Latvian
University located in PSCUH. The MoH, Orphanet Latvian
team and experts from the three university hospitals men-
tioned above met in 2013 and started work on developing
criteria for national centers of expertise [8].
Patient registers
Currently there is no specific register for rare disease pa-
tients in Latvia making it impossible to fully collect and
evaluate information on rare diseases, although the na-
tional plan for rare diseases foresees activities for evalu-
ation and improvement of existing patient registers to
start centralized data collection on rare disease patients
[7,8]. Register of Patients Suffering from Certain Diseases
maintained by the Center for Disease Prevention and Con-
trol (CDPC) contains records on some rare diseases
including cancers and congenital anomalies. Congenital
Anomaly Register is a part of Register of Patients Suffering
from Certain Diseases and it contained data on 11 990
patients with congenital anomalies as of June 2012 [9].
According to data from the Newborn Register 582 cases
of congenital malformations were diagnosed in maternity
wards in 2011 and 677 cases in 2012 [10]. They calculated
in 6.1% of total newborns morbidity rate in 2012. However,
data in the Congenital Anomaly Register is incomplete,
since the register is not functioning optimally, because
there is no mechanism in place that would regulate flow of
information on newly diagnosed congenital anomalies [7].
Therefore the register in its current form requires big
improvements as it is stated in the national plan for rare
diseases. Genome Database of Latvian Population has been
created and is maintained by Latvian Biomedical Research
and Study Center (LBRSC) [11]. This database is a nation-
wide project designed to create identification, storage and
processing system for health and genetic information of
Latvian population for research, preventive and therapeutic
purposes. As of November 2012 the number of partici-
pants recruited in the project (number of collected DNA
samples) was 20 126 [12]. DNA and data collection of
monogenic diseases maintained by Genome Database of
Latvian Population contains more than 800 patient sam-
ples (more than 500 of which for rare diseases) [7].
Rare cancers are included in the National Cancer
Control Program (2009-2015) adopted by the Cabinet
of Ministers in 2009 [13]. According to data of LatvianCancer Register there were 71 166 patients registered
at the end of 2012 [14] (cancer was newly diagnosed in
11 534 patients in 2012). Taking into account that rare
cancers calculate in 24% of the total cancer prevalence
in the EU [15] (annual incidence rate of rare cancers in
Europe is 22% of all cancer diagnoses), the estimated
number of patients with rare cancers in Latvia could be
around 17 080 patients (annually around 2 537 newly
diagnosed patients).
The Cardiovascular Health Improvement Action Plan
(2013-2015) was adopted in 2013 [16]. It includes activities
in the fields of health promotion, improving cardiovascu-
lar disease treatment and early diagnostics of congenital
malformation of the heart. According to data from the
heart disease register of the CCUH clinic of children’s
cardiology and cardiac surgery 152 newborns (0.77%) were
diagnosed with congenital heart disease in 2012, 11.1% of
heart pathologies were diagnosed late and 55.5% of path-
ologies were diagnosed antenatally.
Health care professionals from several university
hospital centers collect rare disease patient data, for
example, since 2007 there is a Pulmonary Arterial
Hypertension (PAH) patient register at the Latvian
Cardiology Center of PSCUH [6]. Center of endocrinology
of PSCUH has created several data bases of patients with
rare endocrine diseases, such as acromegaly, Cushing’s dis-
ease, and MEN (multiple endocrine neoplasia) syndrome
[8]. These data bases were created for follow-up purposes,
as well as to serve as a source of scientific information.
Congenital anomaly register is held by the medical genetics
clinic at the CCUH. According to CCUH data there are re-
cords on 40 cystic fibrosis patients in Latvia as of the end
of 2013 [17], and every year this diagnosis is confirmed in
one child, on average. Data are also collected by rare
disease patient organizations. For instance, according to
Latvian Haemophilia Society data there are around 250
patients with bleeding disorders [7], while Pulmonary
Hypertension Association has data on 51 patients with
diagnosed PAH.
It should be noted that implementation of the e-health
project is planned to be launched in Latvia in 2014.
Within this project data on patient health and received
health care services will be stored centrally. There is also
a pilot plan to use Orpha codes and OMIM codes for
rare diseases within the e-health system to ensure identi-
fication and visibility of rare diseases [8]. Some activities
are currently being implemented including the approval
of an act concerning the plan to include Orpha codes in
the congenital anomaly and cancer registers. It would
allow using e-health system information for obtaining
data on prevalence, diagnostics, and treatment of rare
diseases. If the above mentioned plan was implemented,
making new separate rare disease patient register would
not necessarily be required [7].
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register based study on survival and care of cancer
patients), RARECARENet (information network on rare
cancers), EUROCAT (European surveillance of congenital
anomalies), and EUHASS (European haemophilia safety
surveillance) [6]. Latvian teams also participated in the
following pilot European reference networks for rare dis-
eases: Dyscerne (European network of centers of expertise
for dysmorphology) and PAAIR (patient associations and
alpha-1 international register) [18]. These pilot projects
were financed by the European Commission within the
scope of the Community action program on rare diseases,
including genetic diseases (1999-2007) and the second
program of the Community action in the field of health
(2008-2013). Only one register of rare disease patients
(Latvian cystic fibrosis patient register) is listed in
Orphanet report on rare disease registers in Europe [19],
which means that there is a need to improve information
exchange and optimize flow of information among differ-
ent institutions.
Diagnostics
Newborns are screened for only two rare disorders in
Latvia: phenylketonuria (since 1987) and congenital hy-
pothyroidism (since 1996) [7]. Data on newborns screened
in maternity units are collected in the newborns register
that is supervised by the CDPC [8]. An average of 22
neonates with congenital hypothyroidism and 4 with
phenylketonuria were annually diagnosed through this
neonatal screening program in 2007-2012 [20]. A ques-
tion has been recently raised concerning expanding the
newborn screening by using tandem mass spectrometry
method [7]. Latvian Food and Veterinary Service and
Institute of Organic Synthesis have such mass spectrom-
etry devices, but they are not used for medical purposes
making it a nonsense situation.
Some prenatal and postnatal diagnostic tests for rare gen-
etic diseases are financed by the National Health Service
(NHS) [7], including:
1. Cytogenetic analysis: chromosome analysis with the
standard method and molecular cytogenetic or FISH
(fluorescence in situ hybridization) method;
2. Genetic biochemical analysis: biochemical screening
of pregnant women at high risk for fetal genetic
abnormalities; neonatal screening for phenylketonuria
and congenital hypothyroidism; selective screening of
inborn metabolic disorders (spectrum of amino acids
and organic acids, as well as analysis of oligosaccharides,
mucopolysaccharides and carbohydrates);
3. DNA diagnostics for: spinal muscular atrophy,
hereditary motor and sensory polyneuropathy, long
chain and medium chain fatty acid oxidation
disorders, Huntington’s chorea, fragile X syndrome.Additionally, diagnostics of the following genetic disor-
ders are available within the scientific research projects or
in laboratories of scientific institutions [7]: cystic fibrosis,
hereditary haemochromatosis, Wilson’s disease, Gilbert’s
syndrome, alpha-1 antitrypsin deficiency, several forms of
inherited cancers, and thrombophilia. In some cases clin-
ical university hospitals collaborate and send samples to
LBRSC for genetic testing [8]. For example, genetic testing
of all family members of patients with MEN syndrome
is financed in terms of scientific project. Genetic testing is
available through Medical Genetics Clinic of CCUH,
Molecular Genetics Scientific Laboratory of Riga Stradins
University (RSU), and LBRSC [6]. In recent years amount
of newly diagnosed genetic diseases has increased by about
25% [7] thanks to new diagnostic methods offered by these
institutions. However, despite the progress made in the
diagnostics of genetic diseases, number of patients with
unspecified genetic abnormalities requiring additional in-
vestigation abroad is increasing. Genetic testing in other
EU states is possible through the special E112/S2 forms, if
genetic testing is a health care service usually financed
from the state budget, but this service cannot be provided
in Latvia or cannot be provided within a reasonable period
of time [6]. Mostly it is provided for children with life-
threatening or treatable conditions.
Clinical guidelines for rare diseases have not been ap-
proved at the national level, although center of endocrin-
ology of PSCUH in collaboration with endocrinologists
from RECUH and CCUH issued diagnostic algorithms for
rare endocrine diseases in 2013 [8]. These recommenda-
tions aim to help general practitioners and endocrinolo-
gists to consider rare endocrine diseases in certain types of
patients. PSCUH also organizes post-diploma educational
courses in most areas of medicine, including endocrin-
ology. These courses usually cover not only common clin-
ical conditions but rare diseases as well. As it is with some
rehabilitation services described below, even in such small
country as Latvia there are some regional differences in
availability of diagnostics for rare diseases [7], because
Latvian health care system is organized in such a way
that individual tests requiring modern technologies and
complex manipulations are performed only by the uni-
versity hospitals, which are concentrated in Riga. Further
medical care with less complex health services is provided
by regional multi-profile hospitals.
Rehabilitation services
In parallel with timely and accurate diagnostics and ap-
propriate treatment, rare disease patients require also
proper rehabilitation services. State funding of medical
rehabilitation and amount of provided services, includ-
ing funding for assistive technologies (technical aids), has
decreased significantly over the past few years [7]. There-
fore current availability of rehabilitation services for rare
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solutions are still not found for such assistive technologies
as special mobility devices for muscular dystrophy patients
and oxygen devices for pulmonary hypertension patients.
This problem is particularly actual outside Riga, where
rehabilitation services are limited. Palliative care services
for children are provided by a multidisciplinary palliative
care team set up in CCUH. This team provides inpatient
and outpatient consultative services to families as well as
palliative care services at home for children in Riga. Pallia-
tive care services for children in other Latvian regions and
cities (except Liepaja) are limited, despite the fact that the
government supports development of these services. The
reason of such differences could be partially explained by
the fact, that there are certain requirements for the health
care specialists to provide these services, as well difficulties
are experienced in involvement of multidisciplinary team.
A new service for persons with disabilities (including
disabilities due to rare diseases) was launched in January
2013 [8]. It is a municipality based service providing an
assistant for performing activities outside home, e.g. to
get to work, school or rehabilitation institution. The as-
sistant service is eligible for persons from 18 years of age
with group 1 or group 2 disability (very severe or severe
disability, respectively), or persons aged 5-18 years with-
out dividing disabilities into the groups. The assistant
service is provided on the basis of conclusion of the state
medical commission for the assessment of health condi-
tion and working ability.
Patient organizations
Latvian rare disease patient organization “Caladrius” was
launched in 2009 [6,18]. Mission of this organization is
to provide patients with relevant information in the field
of rare diseases, as well as to support patients and repre-
sent their interests. “Caladrius” established a fund to help
rare disease patients who could not otherwise pay for their
treatment, and in collaboration with CCUH organized two
visits of highly qualified cardiac surgeons in 2011. As a
result complicated operations were carried out for eleven
children with inborn heart pathologies.
There is a number of other rare disease related patient
organizations in Latvia, including Haemophilia Society,
Pulmonary Hypertension Association, Cystic Fibrosis
Society, and Association of People with Special Needs
“Motus Vita” [8]. These organizations often collaborate
with each other, organize rare disease events and cele-
brate annual rare disease day. For example, Pulmonary
Hypertension Association financially supported the first
pulmonary endarterectomy for chronic thromboembolic
pulmonary hypertension (CTEPH) patient in 2013, orga-
nized the summer health camp, and proceeded the oxygen
home care therapy supporting for PAH patients. Latvian
Haemophilia Society intensified cooperation with LithuanianHaemophilia Society in 2013 in order to provide disease
specific training for physiotherapists working with people
with bleeding disorders in CCUH and RECUH. There are
some plans to create an alliance of rare disease patient or-
ganizations and chronic patient organizations at national
level. Until now, there were 8-9 organizations that share
information and collaborate together in this area.
Sources of information on rare diseases
MoH has designated the CDPC as a representative of
Latvia to participate in Orphanet Europe Joint Action
project [6]. Orphanet team is currently hosted by the
CDPC and is in charge of collecting data on rare disease
related services in Latvia, such as specialized clinics,
medical laboratories, ongoing research, registers, clinical
trials and patient organizations. Orphanet national web-
site was launched in April 2012 and is regularly updated
by the Orphanet team. Web based information is also
available for a limited number of conditions through other
sources of information on rare diseases, such as paediatric
rheumatic diseases, lysosomal storage diseases, and through
websites of patient organizations for pulmonary hyperten-
sion, cystic fibrosis, neuromuscular diseases, bleeding disor-
ders, leukaemia and some other forms of cancer.
Research
Generally funding is available for rare disease projects
(through state budget, charities and pharmaceutical
companies) [6] although these funds are not specifically
designed for rare disease research. Rare diseases were not
included in the priority directions of science and research
[8], but a number of scientific research projects in the field
of rare diseases take place in Latvia [7]. As well collabor-
ation networks have been created with researchers from
Baltic States and other countries around the world. Exam-
ples of such projects are researches in:
1. Hereditary liver, lung and mitochondrial diseases
(Scientific Laboratory of Molecular Genetics, RSU);
2. Genetics of inherited cancers (Institute of Oncology,
RSU);
3. Nonsyndromic hearing loss (Clinic of Medical
Genetics, CCUH);
4. Nonsyndromic orofacial clefts, familial melanoma,
MODY (maturity onset diabetes of the young) type
diabetes, congenital muscular dystrophies and
familial hypercholesterolaemia (LBRSC);
5. Genetics and effectiveness of treatment of
acromegaly (PSCUH and LBRSC);
6. Genome analysis of rare hereditary eye disorders
and metabolic abnormalities (collaborative project
with the University of Tartu).
7. Rare cardiovascular diseases. Project coordinated by
Center for Rare Cardiovascular Diseases, John Paul
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Latvian Center of Cardiology, PSCUH and
Lithuanian University of Medical Sciences, Kaunas.
Baltic Metabolic Group annually brings together experts
in the field of metabolic diseases [7]. Research projects on
inherited metabolic diseases in the Baltic region are
carried out within the framework of this group. Latvia
is currently an observer of the E-Rare (ERA-Net for re-
search programs on rare diseases) project [8], however
Latvian funding agencies do not contribute to the IRDiRC
(International Rare Disease Research Consortium) project.
Orphan medicinal products
Pharmaceutical companies submit a single marketing
authorization application to the EMA under the central-
ized procedure. Once granted by the European Commis-
sion, a centralized marketing authorization for orphan
drug is valid in all the EU states (including Latvia).
Whereas decisions surrounding orphan designation and
marketing authorization of orphan medicines are taken
at the EU level, decisions governing pricing and reim-
bursement of orphan drugs are a member state respon-
sibility. State Agency of Medicines (SAM) of Latvia
includes medicinal products registered in Latvia as well
as medicines centrally registered by the EMA in a regis-
ter of medical products of the Republic of Latvia [6].
SAM is also responsible for regular collection and distri-
bution of information on drugs, including orphan medi-
cinal products, as well as for compiling information on
drug safety, evaluating possible risks and coordinating
measures for risk reduction. Inventory of Community
and Member States’ incentive measures to aid the re-
search, marketing, development and availability of or-
phan medicinal products reported that in Latvia SAM is
entitled to make a decision regarding the fee exemption
or reduction for activities associated with the evaluation
or registration of a medicinal product if it (with or with-
out orphan designation) is intended to the treatment of
a rare disease [21]. The Inventory also stated that SAM
may issue distribution authorization for medicinal prod-
uct not registered in Latvia if it is intended for treatment
of a rare disease (for an individual patient on the basis
of prescription or for use in a health care institution on
the basis of a written request). A first level of accessibil-
ity exists for orphan medicines that have not yet been
authorized, the most common being compassionate use.
It covers diseases for which no satisfactory alternative
therapy exists. SAM has approved several programs for
drug compassionate use in Latvian hospitals [22]. The
programs include influenza drugs (oseltamivir and zana-
mivir) for intravenous administration, medicine for
chronic hepatitis C (boceprevir), and drugs for cancer
(Sprycel and Votrient) used in Ph + CML and metastaticsoft tissue sarcoma, respectively. Sprycel is an orphan
drug included in the national reimbursement list C,
while Votrient was originally designated an orphan
medicine, but it was further withdrawn from the EU
register of designated orphan medicinal products upon
request of the sponsor.
Orphan drug availability
Currently 34 orphan drugs are available on Latvian mar-
ket (Table 1), including 6 drugs that are no longer con-
sidered to be orphan medicines in the EU. These drugs
were originally designated orphan medicines, but further
withdrawn from the EU register of designated orphan
medicinal products either upon request of the sponsor
(Afinitor, Glivec, Revolade and Sutent) or at the end of the
period of market exclusivity (Aldurazyme and Ventavis).
Strictly speaking it means that only 28 pure orphan prod-
ucts are available in Latvia calculating in 38.9% out of
72 orphan drugs currently authorized in the EU. Orphan
medicines are distributed by both hospital and community
pharmacies. It should be noted that some of the orphan
drugs were stated as available in SAM medicinal product
register, however they were not considered to be available
in Latvia as they did not meet availability criteria defined
in current study (i.e. drugs were considered to be available
if they were marketed/launched in Latvia according to data
in at least two of the sources mentioned in the Methods
section). For example, Torisel is stated as available in SAM
register, although drug manufacturer has confirmed the
opposite. Additionally individual reimbursement data show
that Torisel was reimbursed for two patients with malig-
nant neoplasm of kidney in 2008. According to the com-
pany, Somavert (which is no longer an orphan medicine in
Europe due to expiration of the period of market exclusiv-
ity) was available shortly after registration, but there was
no demand, so the product currently is not available. As
stated by the wholesalers, Tracleer and Vidaza were once
in stock but are not available anymore. The manufacturers
also confirmed that these products are not available in
Latvia.
There is no information on Gliolan availability provided
in the SAM register, although the product is stated as
available in EUCERD reports, and availability was also
confirmed by the manufacturer and the wholesaler. There
are special requirements for use of Gliolan. It should
only be used by experienced neurosurgeons who have
completed a training course in fluorescence-guided sur-
gery (fluorescence microscope is used in the procedure) in
malignant glioma resection. The Marketing Authorization
Holder (MAH) is obligated to implement mentioned train-
ing course. According to information provided by the
MAH there is one neurosurgeon in Latvia experienced in
utilizing the product. The SAM register provides no infor-
mation on availability of Diacomit, however the product is
Table 1 Orphan drugs available in Latvia
Trade name Active substance Indication Reimbursement
Afinitor* Everolimus Neuroendocrine tumours of pancreatic origin (pNET)
Renal cell carcinoma (RCC)
Aldurazyme* Laronidase Mucopolysaccharidosis I (MPS I) CCUH
Arzerra Ofatumumab CLL Individual
Atriance Nelarabine T-cell ALL Individual
T-cell lymphoblastic lymphoma
Carbaglu Carglumic acid Hyperammonaemia
Cystadane Betaine anhydrous Homocystinuria CCUH/Individual
Diacomit Stiripentol Severe myoclonic epilepsy in infancy (Dravet’s syndrome) Individual
Elaprase Idursulfase MPS II (Hunter syndrome) CCUH
Evoltra Clofarabine ALL
Exjade Deferasirox Beta thalassaemia major with iron overload due to blood transfusion Individual
Gliolan 5-aminolevulinic acid hydrochloride Malignant glioma
Glivec* Imatinib Ph + CML List A





Increlex Mecasermin Primary insulin-like growth factor 1 deficiency CCUH
Jakavi Ruxolitinib Myelofibrosis
Kuvan Sapropterin Phenylketonuria CCUH
Tetrahydrobiopterin deficiency
Litak Cladribine Hairy cell leukaemia
Mozobil Plerixafor Haematopoietic stem cell transplantation in lymphoma or multiple
myeloma patients
Individual
Myozyme Alglucosidase alpha Pompe disease
Nexavar Sorafenib Hepatocellular carcinoma Individual
RCC
Nplate Romiplostim ITP Individual
Orfadin Nitisinone Hereditary tyrosinaemia type 1
Pedea Ibuprofen Patent ductus arteriosus in preterm newborns
Peyona Caffeine citrate Primary apnea of premature newborns
Revatio Sildenafil PAH Individual
Revolade* Eltrombopag ITP Individual
Sprycel Dasatinib Ph + CML List C
Ph + ALL Individual
Sutent* Sunitinib GIST Individual
RCC
pNET
Tasigna Nilotinib Ph + CML List C
Tobi Podhaler Tobramycin Pseudomonas aeruginosa infection in cystic fibrosis patients
Ventavis* Iloprost PAH
Volibris Ambrisentan PAH Individual
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Table 1 Orphan drugs available in Latvia (Continued)
Votubia Everolimus Renal angiomyolipoma or subependymal giant cell astrocytoma
associated with tuberous sclerosis complex
Wilzin Zinc acetate dihydrate Wilson’s disease Individual
Yondelis Trabectedin Soft tissue sarcoma
Ovarian cancer
*Afinitor, Aldurazyme, Glivec, Revolade, Sutent and Ventavis are no longer considered to be orphan medicines in the EU.
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vidually reimbursed annually in 2008-2012. There is also
no information on Aldurazyme availability in the SAM
register, although the company confirmed that the product
is available. Aldurazyme is also stated as available in the
EUCERD 2013 report. Additionally, it was purchased by
CCUH within the “Medicinal treatment for children with
rare diseases” program in 2014.
For some orphan drugs the manufacturers stated that
these products would be available on demand if there
was a patient requiring them, as it is in case of Atriance,
Orfadin, Yondelis, Savene, Litak and Vpriv. Yondelis has
been provided by the company free of charge for one
time, but it did not affect further availability of the drug.
Several packages of Ventavis are bought quite rarely and
are available only for patients in PSCUH. Afinitor is also
available, and according to the company’s information
there could be around six patients in Latvia requiring
treatment with this drug.
Orphan drug pricing and reimbursement
There is no specific policy in place for pricing of orphan
drugs in Latvia. Costs related to rare diseases and or-
phan drugs are currently included in the national health
care budget [6,7]. Drug reimbursement covers drugs
which are included in the national reimbursement drug
list, or based on the medical council’s decision, drugs
can also be reimbursed within the framework of individ-
ual reimbursement system with a limit of 14 229 Euro
per patient per year [23]. The main principle of drug in-
clusion in the reimbursement list is that the drug should
be therapeutically and cost effective, i.e. decision is value
based and is not specific to orphan drugs. The national
reimbursement list consists of three parts: list A cover-
ing therapeutically equivalent drugs (generics); list B that
consists of drugs without therapeutic equivalent; and list
C that contains drugs for which the annual cost exceeds
4 269 Euro per patient and the manufacturer is obliged
to cover treatment expenses for a certain number of
patients with his own resources (not less than 10%). The
NHS evaluates therapeutic value, price, expected budget
impact and cost-effectiveness for each drug before it is
included in the reimbursement list. Drug price is com-
pared with the prices in other EU countries. The price ofthe reimbursed medicine should not be higher than
the third lowest price in the Czech Republic, Denmark,
Romania, Slovakia and Hungary, and shall not exceed
the price of the medicine in Estonia and Lithuania.
Health care of rare disease patients under 18 years of
age is currently evaluated satisfactorily [7]. Since 2009,
several orphan medicinal products for children are pro-
vided as a part of the state funded program “Medicinal
treatment for children with rare diseases” coordinated
by CCUH [6,7]. Five orphan drugs (14.7%) were provided
within this program in 2010-2014: Elaprase, Cystadane,
Increlex, Kuvan and Aldurazyme. However, after reaching
the age of 18 and moving into adult patient group, most
patients lose state support for reimbursement of medica-
tions and rehabilitation services. Another positive example
of rare disease management in Latvia is a care of children
with cystic fibrosis with a multidisciplinary team approach
involving paediatricians, geneticists, pulmonologists, psy-
chologists and social workers.
Orphan medicinal products are partially available via
the reimbursement system. Glivec, Sprycel and Tasigna
are the only three drugs (8.8%) included in the positive
reimbursement list. Glivec was among the first orphan
drugs available in Latvia (since 2001). It became first and
at that time the only orphan drug included in reimburse-
ment list C and reimbursed for Philadelphia chromosome
positive chronic myeloid leukaemia (Ph + CML) second
line treatment. Starting from May 2013, Glivec was moved
to the reimbursement list A, because cheaper generic
drugs became available that changed prescribing and re-
imbursement criteria for imatinib. Currently it can be pre-
scribed by haematologist or paediatric haemato-oncologist
based on the council’s decision and is reimbursed for
patients with Ph + CML or acute lymphoblastic leukaemia
(Ph + ALL), bone marrow transplant, and gastrointestinal
stromal tumours (GIST). Sprycel and Tasigna are reim-
bursed based on the haematologist council’s decision
for adult patients with Ph + CML in the chronic phase
if prior therapy with imatinib is not effective (second line
treatment).
Not more than two percent of the national drug reim-
bursement budget is intended to individual reimbursement
with limitation up to 14 229 Euro per patient per year.
Fifteen orphan medicinal products (44.1%) were provided
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2012: Arzerra, Atriance, Cystadane, Diacomit, Exjade,
Glivec, Mozobil, Nexavar, Nplate, Revatio, Revolade, Sprycel,
Sutent, Volibris and Wilzin. Until January 2013, Revolade
and Arzerra were reimbursed within the framework of indi-
vidual reimbursement system. Starting with January 2013,
regulation of the Cabinet of Ministers on individual drug
reimbursement was changed. According to the new regula-
tion the individual reimbursement can be provided only in
cases when diagnosis is not included in the reimbursement
list or the diagnosis is included in the list, but there are no
drugs included in the reimbursement list for treatment of
this diagnosis. In case of Arzerra and Revolade both diag-
noses, chronic lymphocytic leukaemia (CLL) and immune
(idiopathic) thrombocytopenic purpura (ITP), respectively,
are included in the reimbursement list with some therapy
alternatives available, making Arzerra and Revolade prac-
tically inaccessible for patients. Similar situation may refer
to other orphan drugs previously provided within the
individual reimbursement mechanism. For instance, only
about a half of Volibris price is covered by the state within
the individual reimbursement system, while the rest is
provided by the company or paid by patients. In case of
Nexavar the state coverage is even smaller accounting in
less than a quarter of price, therefore it is almost exclu-
sively bought by individual patients for their own money
(for some patients a quarter of price is paid by the NHS,
but the rest is paid by the manufacturer). However, there
are some positive exceptions, for example, reimbursement
costs of Revatio do not exceed limit of 14 229 Euro and it
is therefore fully covered by the state. Besides, Revatio
was reimbursed most frequently among all orphan drugs
within the individual reimbursement system in 2008-2012.
A significant problem faced by rare disease patients is
associated with special nutrition and medical foods. While
some of these foods are vital for rare disease patients, they
are usually not classified as medicinal products in Latvia.
For some rare diseases medical food often is the main or
even the only way in which food is taken, and its discon-
tinuation can be life-threatening. So far there is no standard
procedure (regulation) in place for registration of medical
food in Latvia [7], and the manufacturer can choose the
most appropriate registration procedure to him, most often
based on cost considerations. As a result, it is not possible
to adapt the same reimbursement arrangement for these
foods as it is for medicinal products included in the na-
tional reimbursement drug list.
Discussion
Development of the national plan for rare diseases seems
to be an important initial step towards improving situ-
ation in this field in Latvia. However, there are currently
no official designated centers of expertise as well as no
specific register for rare diseases, making it impossible tofully collect and evaluate information on rare diseases.
Newborn screening for only two rare disorders is cer-
tainly not sufficient resulting in recent discussions con-
cerning expanding of the screening by using tandem
mass spectrometry method. The situation appears to be
similar in other Baltic States. Lithuanian national plan
for rare diseases was approved in 2012 [8] and it was the
first plan in Baltic region. Estonian plan was finalized and
submitted to national authorities in 2013. Lithuania and
Estonia are among those countries with a low neonatal
screening coverage. Neonatal screening programs are
currently implemented only for phenylketonuria and
congenital hypothyroidism. There are also plans to ex-
pand screening and introduce tandem mass spectrom-
etry analysis in both countries. There are currently no
official designated centers of expertise for rare diseases
in all Baltic States. Some centers are recognized by reputa-
tion only. Latvia and Lithuania have plans to designate
centers of expertise for rare diseases in the future, while
Estonia has no such plans. Similarly to Latvia, Lithuania is
planning to implement the e-health information system
and establish electronic platform based disease registers
(including rare diseases). In Estonia, all health related
information is already collected in the electronic health
information system, which can be updated and used to
extract statistical data about rare diseases.
It has been found that even in such small country as
Latvia there are some regional differences in availability
of diagnostics, treatment and rehabilitation services for
some rare diseases, since university hospitals, scientific
and research institutions are concentrated in the capital
and the largest city of Riga. There are also differences in
availability of health care services between paediatric and
adult patient groups, giving that five orphan drugs were
provided within the CCUH program. Patient organizations
play an important role in increasing awareness and provid-
ing necessary pressure on society and policy makers.
Several patient organizations support patients and rep-
resent their interests, including general rare disease pa-
tient organization “Caladrius” and patient organizations
for specific rare disorders. Public awareness is also sup-
ported via Orphanet national website.
Orphan medicines are distributed by both hospital and
community pharmacies. Currently 34 orphan drugs are
available, including 6 drugs that are no longer considered
to be orphan medicines in the EU, concluding that major-
ity of orphan drugs authorized in the EU are not available
in Latvia. Orphan medicinal products are partially avail-
able via the reimbursement system, with only three drugs
included in the positive reimbursement list, all indicated
for Ph + CML. Another pathway for getting orphan drugs
is individual reimbursement with limitation up to 14 229
Euro per patient per year. Fifteen orphan medicinal prod-
ucts were provided within this program. Annual limit of
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ering high price of orphan drugs. Therefore treatment
costs often exceed this limit and the rest of expenses not
covered by the NHS should be paid by the patient or pro-
vided by the manufacturer. The situation with access to
orphan drugs has even worsened with recent changes in
terms and conditions of new regulation on the individual
reimbursement making some orphan drugs practically
inaccessible for patients. Another significant issue is lack
of standard procedure (regulation) for registration and
reimbursement of special nutrition and medical foods.
Denis et al. compared rare disease and orphan drug mar-
kets in six European countries [24]. France, Italy, Sweden
and UK have dedicated centers of reference for rare dis-
eases. Besides, there are no official centers of reference in
Belgium and the Netherlands, but several medical centers
fulfill this role. France, Italy and the Netherlands have
implemented additional policy measures and research
incentives to promote research and development of or-
phan medicines. Marketing authorization of orphan drugs
is responsibility of the EU, but France has in place a
domestic procedure for authorization of orphan products
(for temporary use before getting approval from EMA).
There are programs for compassionate use of orphan
drugs in Belgium, France, Italy, the Netherlands, and UK,
but there is no legislation governing compassionate use in
Sweden. Some similarities and differences can be found
when comparing Latvian situation with the above men-
tioned European countries. For example, there are no offi-
cial centers of reference in Latvia, but several medical
centers fulfill this role similarly to the process in Belgium
and the Netherlands. Generally some funding is available
for rare diseases and several research projects take place
in Latvia, although these funds and incentives are not
specifically designed for rare disease research. As in most
EU countries there is no domestic orphan drug autho-
rization procedure, but several programs for orphan drug
compassionate use take place in Latvian hospitals. Belgium,
France, Italy and the Netherlands compare the price of or-
phan medicine with the price in other countries [24], while
Sweden and UK have free pricing system. All countries in-
cluded in the above mentioned study consider the budget
impact of orphan drugs in the reimbursement application,
except Sweden, whereas cost-effectiveness is considered in
all countries, except Belgium. In Latvia, there is no specific
policy for the pricing and reimbursement of orphan drugs.
The NHS evaluates therapeutic value, price, expected
budget impact and cost-effectiveness for each drug be-
fore it is included in the reimbursement list. Drug price
is compared with prices in the following EU countries:
Czech Republic, Denmark, Romania, Slovakia, Hungary,
Estonia and Lithuania. Comparison with these mostly
smaller Eastern European countries (excluding Denmark)
seems to be very logical taking into considerationgeopolitical location of Latvia, lower GDP level, small
population and market size. It can be expected that
Latvian situation is likely to be closer to these countries.
Some studies in the field of rare diseases conducted in
other Eastern and Southern European countries recently
came to light. For instance, in Bulgaria there is no na-
tional register or centers of expertise for rare diseases
[25]. Regulation of compassionate or off-label use of or-
phan drugs is also missing. Price of orphan medicines
which are going to be included in the reimbursement list
is compared with reference prices in a set of EU coun-
tries (including Baltic States). Before inclusion in reim-
bursement list drugs are also assessed for therapeutic
value and social significance, but cost-effectiveness of
the drug is not considered. The allocation of funds for
orphan medicines is made once per year and it is based
on the previous year’s budget. Neither national register,
nor policy measures, and research incentives for rare
diseases exist in Serbia [26]. Cost-effectiveness, budget
impact, and the need for a given treatment are taken
into account when assessing reimbursement application
of a drug. Orphan medicinal products are reimbursed
from the national health insurance fund, which reim-
burses only medicines that are registered in Serbia [8].
There is no centralized marketing authorization proced-
ure in place since Serbia is not the EU Member State.
Domestic registration is therefore required, that can take
additional time and delay patient access to orphan drugs.
Compassionate and off-label use is not recognized by
the health insurance system in Serbia, although there is
a special fund for reimbursement of the treatment of
paediatric patients with metabolic diseases requiring en-
zyme replacement therapy. Around 2.6 million Euro was
planned for this purpose in 2014.
31 orphan drugs were marketed in Belgium in 2008 [24];
35 drugs in France in 2007; 23 drugs in Italy in 2007; 40
drugs in the Netherlands in 2008; 28 drugs in Sweden in
2008; and 20 drugs in UK in 2006. The situation on orphan
drug reimbursement in studied countries was as follows:
32 orphan drugs were reimbursed in Belgium (2009); 35 in
France (2007); 21 in Italy (2007); 32 in The Netherlands
(2009); 28 in Sweden (2008); and 12 in Scotland (2008).
Current study was conducted in 2014 and it found that 34
orphan drugs (28 pure orphan products) are available
in Latvia, and only three orphan drugs are included in
the positive reimbursement list. This number is extremely
small especially considering time difference between the
studies and growing number of orphan medicinal products.
There were 47 orphan drugs on the European market by
the end of 2008 [24], while 72 orphan drugs are currently
authorized in the EU.
Surveys on orphan drug availability in Europe had
pointed out unacceptable delays and inequalities in rare
disease patients’ access to their medicines. Especially
Logviss et al. Orphanet Journal of Rare Diseases 2014, 9:147 Page 11 of 13
http://www.ojrd.com/content/9/1/147countries with a small population suffer from a longer
delay in availability of drugs. In 2007, overall lowest avail-
ability of orphan drugs was demonstrated in Estonia and
Lithuania [27]. In 2010, the number of patients with po-
tential access to orphan drugs ranged from 34% in Greece
up to 98% in France [28]. The price also varied between
the countries, and in some countries it was up to 160%
higher than the lowest European price. Another European
study found that differences in annual costs per patient
between the EU countries for a given orphan drug may
reach 70% [29]. Newer EU Member States are often facing
budget restrictions with healthcare budgets much lower
than compared to older Member States [30], thereby
reimbursement levels can differ. Thus number of avail-
able (marketed) orphan drugs in Bulgaria was 22 and
16 of them were accessible (reimbursed) for patients in
2011 [25]. Iskrov et al. point out that this is an import-
ant issue especially for Eastern European countries, as a
big part of orphan drugs are not priced and reimbursed
in many countries. In this geographical and economical
region the price level of orphan drugs is not among the
lowest in the EU, and that could be explained by the
small market size represented by these countries. Serbia
might be mentioned as another example, where only four
orphan medicines were reimbursed [26]. Authors also sug-
gest that gross domestic product (GDP) value may partly
explain differences in the level of orphan drug reimburse-
ment among the European countries, since Serbia is a
country with a low GDP. Baltic States are also among the
countries with a low GDP. In Lithuania, budget assigned
for reimbursement of orphan medicines is limited and in-
sufficient (1.89 million Euro in 2006) [31], therefore access
to health care services and orphan drugs in some cases is
restricted. 29 orphan medicinal products were marketed
in Lithuania in 2011 [8], and about 3 million Euro was al-
located for reimbursement of medicinal products and de-
vices for rare diseases in 2013. There is no specific pricing
and reimbursement policy for orphan drugs in Estonia.
They are reimbursed on the same basis as other medicines.
20 orphan drugs are fully reimbursed by the Estonian
health insurance fund. The fund has also reimbursed off-
label drugs and medical foods for rare disease patients.
As stated by Drummond et al., because of the small
market, orphan drugs are often very expensive [32]. High
price may also originate from marketing exclusivity, as
well as costs of research and development, that should be
recovered from a small number of patients. With standard
economic evaluation, these drugs usually do not prove to
be cost-effective and it, taking into account their high
price, means that patient access may be limited. According
to Picavet et al. orphan designated drugs have higher me-
dian price (138.56 Euro) than non-designated drugs (16.55
Euro) for rare disease indications [33]. Moreover, price
of an orphan drug is higher for a disease with a lowerprevalence [29]. Although orphan drugs with an alterna-
tive have lower annual cost per patient than those without
an alternative [34]. Pharmaceutical companies have to
comply with different pricing and reimbursement ap-
proaches in each EU country, thereby raising the price of
orphan drugs [35]. Moreover, prices of drugs distributed
through the hospital pharmacies are not regulated in most
European countries, but are negotiated directly between
the manufacturer and the hospital [34]. According to
Simoens, there is a need for a transparent and evidence
based approach towards pricing and reimbursement of or-
phan drugs.
The economic impact of orphan drugs on national
budget is growing, for example, in France representing a
total budget of 1 billion Euro in 2009 [30]. The annual per
patient cost of orphan drugs varied between 1 251 Euro
and 407 631 Euro, with the median cost being 32 242 Euro
[36]. The share of the total European pharmaceutical mar-
ket represented by orphan drugs was 3.3% in 2010, and it
was predicted by Schey et al. to increase to a peak of 4.6%
in 2016. Another analysis estimated that orphan drugs
constituted 1.9% of total drugs expenditure in Belgium in
2008, and predicted it to increase to about 4% in 2013
[37]. While the average budget impact of orphan drugs
accounted for 1.7% of the total pharmaceutical expend-
iture across France, Germany, Italy, Spain and the UK
in 2007 [38]. In recent study the observed orphan drug
budget impact was 2.5% of total pharmaceutical sales in
Sweden and 3.1% in France in 2012 [39]. Precise impact
of orphan drugs on Latvian budget has not been deter-
mined yet. In the above mentioned studies orphan drug
budget impact was around 2-3% of total drugs expend-
iture depending on market, though the studies were
mostly focused on countries with a high GDP. It can be
estimated that the budget impact of orphan drugs in
Latvia, as a country with a low GDP, is smaller taking
into account budgetary restrictions, small market size,
and high price of orphan drugs. Recent study evaluated
whether a country’s GDP and health technology assess-
ment (HTA) organization influences the orphan drugs’
market uptake [40]. Market volumes were highest in
countries with a high GDP. Latvia was included in the
cluster of countries with a low GDP and a formal HTA
organization together with Hungary and Poland. This
cluster had the lowest sales of orphan drugs as well as
the lowest contribution of total orphan drug market sales.
Other Baltic States were included in the cluster with a low
GDP and no HTA organization. For this group of states
sales of orphan drugs and contribution of total orphan
drug market sales were the second lowest. It should be
noted that only five out of 17 orphan drugs selected for
the analysis were launched in Latvia, whereas all orphan
drugs were launched in France, Spain and the UK. The
sales also varied substantially. In Latvia, only 8 000 Euro
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pared to approximately 560 000 Euro in France. The con-
tribution of orphan drug sales to total market sales was
also lowest in Latvia, and percentages varied from 0.07%
in Latvia to 1.90% in Estonia. However, the authors ac-
knowledged that this study suffered from several limi-
tations, data restrictions and differences in data quality
between the countries. As well not all orphan drugs
available in Latvia were included in the analysis. 17 orphan
drugs were selected and only five of them were recognized
as launched in Latvia. According to data from the current
study there are 34 orphan drugs (28 pure orphan products)
available on Latvian market. Moreover, Glivec, Elaprase
and Revatio were not selected in the above mentioned
study. These drugs could have a major impact on total
orphan drug market sales in Latvia. Elaprase and Revatio
were purchased most frequently among all orphan drugs
within the CCUH program and individual reimbursement
system, respectively. Glivec was the first and, until recently,
the only orphan drug included in the positive reimburse-
ment list. This blockbuster anticancer drug accounted for
34% of total orphan drug sales between 2000 and 2012 in
Sweden, and for 27% in France [39]. However, Glivec is no
longer considered to be orphan medicine in the EU since
2012, as well generic analogues of imatinib became avail-
able in 2013. This fact can affect the price and sales of
the product. Considering dynamic nature, and between
countries differences in orphan drug markets (and drug
markets in general), budget impact of orphan drugs in
Latvia should be assessed more accurately. Specificity
of the small market with a low GDP, peculiarities of drug
reimbursement system, and budgetary restrictions faced
by health care system should be taken into account.
Conclusions
The majority of orphan drugs authorized in the EU are not
available in Latvia, moreover those drugs that are available
are often not accessible because they are insufficiently re-
imbursed by the state, and are too expensive to be covered
by patients. Diagnostics of rare diseases (including new-
born screening) also require improvements. The develop-
ment and approval of the national plan for rare diseases is
an important step towards improving the situation in the
field of rare diseases. However, there is still a lot to do and
further action is required to improve access to information
on rare diseases for both health care professionals and pa-
tients. The creation of a rare disease patient register and
centers of expertise would allow to collect and evaluate in-
formation on specific rare diseases, that would greatly im-
prove the current situation and coordination of further
activities in the field. Data collected through the register
should also be used to assess the long-term effectiveness
and cost-effectiveness of orphan medicines and should be
harmonized at the EU level. Early detection and preventionof rare diseases, integrated health care for patients, timely
access to orphan drugs and continuing education of health
care professionals play crucial role in improving quality of
life of patients suffering from orphan diseases. Many of
these activities are included in the national plan for rare
diseases and most of them are currently in the process of
development.
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